Greenstone Biosciences, Inc. and Intel Corp. Launch Strategic Collaboration to Scale Human-Centric Drug Discovery

Key Terms

induced pluripotent stem cells medical

Induced pluripotent stem cells (iPSCs) are adult cells that scientists have reprogrammed to behave like embryonic stem cells, meaning they can become many different cell types. For investors, iPSCs matter because they are a flexible platform for developing new drugs, testing safety, and creating personalized therapies; think of them as blank building blocks that can be used to prototype treatments and reduce development risk before large clinical bets.

edge ai technical

Edge AI refers to artificial intelligence systems that process data directly on local devices or nearby servers rather than sending information to distant data centers. This allows for faster decision-making and real-time responses, similar to how a home security camera can instantly detect motion without needing to connect to a remote server. For investors, edge AI represents a growing trend toward more efficient, responsive technology that can create new opportunities across various industries.

new approach methodologies (nams) regulatory

New approach methodologies (NAMs) are modern testing tools and strategies—such as computer models, advanced cell-based assays, and lab-grown tissues—that replace or supplement traditional animal tests to evaluate safety, toxicity, and biological activity of drugs, chemicals and products. For investors, NAMs can shorten development timelines, lower testing costs, and reduce regulatory uncertainty, much like switching from slow manual inspection to faster automated quality checks in a factory.

preclinical testing medical

Preclinical testing is the set of laboratory and animal studies done to see whether a drug, medical device, or therapy is likely to be safe and effective before it is tried in people. Think of it as prototype testing in a workshop: it looks for obvious safety problems, measures how the product behaves in the body, and provides the data regulators require to allow human trials. For investors, preclinical results are an early signal of technical risk, development timeline, and whether a program can advance toward clinical testing and potential commercialization.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Combining human iPSC biology and AI computing to accelerate drug discovery, improve drug safety, and advance precision medicine.

PALO ALTO, Calif.--(BUSINESS WIRE)-- Greenstone Biosciences, Inc. announces a collaboration with Intel Corp. (NASDAQ: INTC) to accelerate AI-enabled drug discovery using Greenstone’s large-scale, human biobank of induced pluripotent stem cells and Intel’s Edge AI advanced computing and AI infrastructure. Intel and Greenstone are working together to speed up the development of new medicines. The collaboration combines state-of-the-art human genetics and biology from Greenstone with Intel purpose-built silicon – to scale data processing, storage, and analysis. Greenstone has built the world’s largest human biobank of induced pluripotent stem cells (iPSC).

“This collaboration represents an important step toward more human-centered drug development,” said Joseph C. Wu, M.D., Ph.D., Co-Founder of Greenstone Biosciences and Director of the Stanford Cardiovascular Institute (SCVI). “By combining our iPSC-based systems with Intel’s advanced computing architecture, we identify patient-specific response patterns, improve prediction of adverse drug effects, and advance new medicines more quickly and at a lower cost.”

The collaboration also supports growing US FDA regulatory momentum toward New Approach Methodologies (NAMs) (FDA Modernization Act 3.0) along with biotech and pharmaceutical industries that complement traditional animal studies and improve the translational relevance of preclinical testing. By combining human cellular models, population-scale datasets, and AI-enabled analytics, Greenstone and Intel aim to help advance the next generation of drug safety assessment and new medicines.

For a replay of Intel’s Computex 2026 keynote address, highlighting collaboration with Greenstone, click here: link, video, (57:45)

Learn more about the implementation and opportunities for NAMs in drug discovery and development here: Wu et al., 2026; Science, Liu et al., 2026; Cell, Herron et al., 2025; Nature.

About Greenstone Biosciences, Inc.

Greenstone Biosciences, Inc. (Silicon Valley, CA) is a biotechnology company based in the Stanford Research Park and co-founded by Joseph C. Wu, M.D., Ph.D. (Professor & Director of Stanford Cardiovascular Institute). Greenstone is funded by Walden Catalyst, Mayfield, Prosperity 7 Ventures, and others. The company specializes in New Approach Methodologies (NAMs), clinical genomics, iPSC platform, artificial intelligence/machine learning, and drug development. Greenstone has extensive expertise in generating patient-derived human organoids for disease modeling and drug discovery. https://greenstonebio.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20260619892511/en/

For more info, please contact Jade T. Chao, JD, MPH at jadechao@greenstonebio.com.

Source: Greenstone Biosciences, Inc.